Insys Therapeutics (INSY) Tops Q3 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Insys Therapeutics Reports Record Third Quarter 2015 Results
November 5, 2015 6:50 AM ESTAnnounces Senior Management Changes and Appointments
Announces Stock Repurchase up to $50 Million
PHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced financial results for the three- and nine-month periods ended September 30, 2015. Highlights of and subsequent to the third quarter of 2015 include:
Quarter Highlights:
Total net revenue increased to $91.3 million compared to $58.3 million for the third quarter of 2014;Revenue from Subsys® (fentanyl sublingual spray) was $91.1 million,... More